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Episode 60: A Formidable Foe 
Chris Dall: [00:00:06] Hello and welcome to the Osterholm Update, covid-19, a podcast 
on the covid-19 pandemic with Dr. Michael Osterholm. Dr. Osterholm is an 
internationally recognized medical detective and director of the Center for Infectious 
Disease Research and Policy, or CIDRAP, at the University of Minnesota. In this 
podcast, Dr. Osterholm will draw in more than 45 years of experience investigating 
infectious disease outbreaks to provide straight talk on the covid-19 pandemic. I'm Chris 
Dall, reporter for CIDRAP News, and I'm your host for these conversations. Welcome 
back, everyone, to another episode of the Osterholm Update podcast. At a Fourth of 
July celebration held this past weekend on the White House grounds, President Joe 
Biden told the gathering of more than 1000 people to think about how far the nation has 
come over the past year. Well, the virus hasn't been vanquished, the president said, we 
know this, it no longer controls our lives, it no longer paralyzes our nation, and it's within 
our power to make sure it never does again. The president does have cause for 
optimism. Covid-19 cases and deaths remain at all time lows nationwide. And yet with 
the highly transmissible Delta variant of the coronavirus spreading in the US and 
causing new surges in states with low vaccination rates, concerns are emerging about 
what the coming weeks and months will look like in those parts of the country. The new 
questions are being raised about the potential need for booster shots for the vaccinated. 
What happens from here in the US and how public health experts and government 
officials communicate to the public about a virus that is diminished but not yet 
vanquished will be among the topics on this week's episode of the podcast. We'll also 
provide an update on the international situation, discuss the latest news on the Delta 
variant and how the vaccines are holding up against it, answer covid query, and tell you 
about a beautiful place that helped one of our listeners get through the pandemic. But 
first, we'll begin with Dr. Osterholm's opening comments and dedication. 
 
Michael Osterholm: [00:02:02] Thanks, Chris. It's great to be with all of you again, 
thank you for joining us on this podcast. We very much appreciate you taking time to 
join us and trying to understand the world of covid-19. I hope that all of you are having 
an enjoyable summer for those in the northern hemisphere. And for those in the 
Southern Hemisphere, we recognize that your summer is getting closer. Today is going 
to be, I think, one of the most challenging podcasts we've put together. And, you know, 
I've said that in the past, but I think you'll understand as we go through the information 
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we're going to cover today, that the unknown makes predictions about the future very 
difficult. And if there was ever a time for a dose of super humility, it's going to be on this 
podcast today in terms of trying to understand where we're at and where we're going. 
Today's dedication for the podcast reflects the importance of the single most critical tool 
we have in responding to this pandemic. It's called vaccine. You know it well. And we're 
going to talk a lot about vaccines today. This podcast is dedicated to those who are on 
the front lines, making every effort they can to get additional people vaccinated day after 
day after day, sometimes very challenging because those who refuse to get vaccinated 
respond in unfortunate ways. It's also challenging to watch individuals who are close to 
getting vaccinated, who then unfortunately do become infected with covid-19 and end 
up in hospitals and in some cases dying. So today, this dedication is for all the front line 
vaccine workers, wherever you are, whatever position you're in, whatever you're doing 
to get people vaccinated. We dedicate this podcast to you. 
 
Chris Dall: [00:03:56] Mike, as we look at the international situation more than a year 
and a half into this pandemic, the coronavirus continues to find new vulnerable 
populations in countries that have already seen multiple waves of infection. With only a 
fraction of the globe vaccinated and the ability of this virus to mutate into more 
transmissible versions now well-established, is there any end in sight? Is there any 
chance that the virus burns itself out? 
 
Michael Osterholm: [00:04:23] As I noted in the opening, this podcast is going to be 
filled with humility because in fact, I think that the more I study and understand what's 
unfolding with this pandemic, the more I question what the future might look like and 
why. And for all of you out there who want solid answers with a roadmap to completion 
for the pandemic, this is probably not the podcast you want to listen to. For those of you 
that are struggling like so many of us, to try to understand each week, each month what 
the pandemic means, what it will mean for us here in the United States, for the rest of 
the world, stay tuned, this is your podcast. Let me just start out by really going over 
points that we've covered many times in this podcast. When we were into this pandemic 
in those first 12 months or so, we really didn't fully understand or appreciate the 
importance of variants with a coronavirus infection. Remember, early on we thought that 
that was kind of like describing yellow cars, red cars, green cars and blue cars, but 
they're all the same car. These genetically changed viruses through mutation processes 
really were not involved in functional aspects of the disease, didn't make it more 
infectious, didn't mean that they cause more severe illness, and it surely wasn't about 
evading the immune protection that might have come from vaccines or from previous 
natural infection. But then we did understand at the end of last year that there were 
important considerations with these variants. And since that time, we've continued to 
learn on almost a daily basis that this virus is in much more control of what it's doing 
than anything we're doing, other than vaccination. When I think about where we were 
last January, February, there was a part of me that had felt some confidence in being 
able to say, you know what, this thing is following exactly the course that I anticipated. 
As some of you know, last summer, I made the case that there would be summer 
activity, substantial activity that was in the southern hemisphere. In the fall, I said, you 
know, the worst is yet to come. And despite the fact many didn't want to believe that we 
saw October, November with the upper Midwest and the northeastern states lighting up 
big increases, we saw the South lit up again in January. Globally, we saw countries that 
had not had major activity suddenly emerge with major activity. And I felt like we kind of 
know what this is going to do. We can anticipate it. And then along came B117 or what 
we call alpha variant now. You may recall how that lit up in Europe in January and 
February, started to spread around the world. And we said, you know, it's going to be a 
matter of just weeks before it becomes the dominant variant in the United States. This is 
a variant that is at least 40 to 75-80 percent more infectious than the previous strains of 
the virus we dealt, it was more likely to cause severe illness. Buckle your seat belt. 
North America, you're going to get hit hard come March, April. Well, you know what? 
North America didn't. Michigan did, Minnesota did, why the rest of the United States 
didn't light up, even though we watched this variant spread through the country. We 
don't know. I was one of those that thought it was going to be a real challenge. This was 
my first real bout with humility and the need to say, wait a minute, this didn't do what 
you might have expected it to do. I've never seen a respiratory transmitted infectious 
agent light up a state like Michigan and yet not cause the same kind of phenomena in 
the adjoining states. What was going on there? I don't know why. So now here we are 
looking into a new variant, the Delta variant, and it's the thing everyone's talking about. 
People are making all kinds of predictions about it. And today, I'll share with you this is 
what I think it will do. But at the same time, I have to be honest and say maybe it will be 
like B117, not quite like that. I think it's clear that the initial information we have today 
supports the fact that it's not going to be like B117. Globally, we're seeing the same 
thing. I also will comment today on the issue of seasonality. You know, I hear a number 
of my colleagues who are on the media circuit saying, oh, no, this is going to be an easy 
summer. It will be a fall/winter surge we have to worry about. And I've been very 
skeptical of that because everything I've seen so far says there's no evidence of 
seasonality, whether it's the Northern/Southern Hemisphere occurrence, whether it is, in 
fact, when surges occur in countries. And I think right now what we're beginning to see 
in the United States is potentially a major surge in unvaccinated individuals with Delta 
variant. This is us right now. This is summer. This isn't fall or winter. And for those who 
seem to have postponed the need to consider what the Delta variant may do now, I 
think are going to be surprised that it won't be a fall/winter surge. It will be a summer 
surge with potentially tails into the fall/winter. So when we look at this issue of where 
we're going, the next question is what will be the new variants of the future? And I know 
people keep talking about variant development in countries like the United States, 
where there's limited vaccination in certain populations. But I keep reminding everyone, 
remember, there are 6.4 billion people living in the low and middle income countries of 
the world, for which vaccine is almost nonexistent. Today, only seven percent of the 
entire world's population are vaccinated against this virus, seven percent. That's it. And 
most of those who are living in the low and middle income countries who won't have 
access to this vaccine for months and months to come, that's where the new variants 
are going to continue to come spinning out of in the large numbers. And I don't know 
what will be the next Delta plus or the next Delta plus, plus, plus. And I think that this is, 
again, where the humility comes in. We must say, you know, this is what we have seen 
happen from going from those variants of last July, last September, to the variant Alpha, 
to the variant Delta. What will be the next one that will be a major challenge and will it 
would be worse? Can they get worse? Maybe not. Will they be more infectious? Will 
they, in fact, cause more serious illness? Will they evade the immune protection of the 
vaccines even more than the current variant Delta does? So I think that to answer the 
question, will this burn out, no it's not going to. This is going to be with us for a long 
time, if not forever. Can we bring it under better control? Absolutely. If we can vaccinate 
the world right now, we'd be in a very different place. Are we doing enough to get the 
world vaccinated? Absolutely not. At this point, we are taking a garden hose to a forest 
fire, and it's really important to understand that we have to realize that taking care of the 
entire world with this virus is going to be everything about taking care of any place in the 
world, including the United States. So let me just leave it by saying, we are not going to 
run out of reasons to do this podcast for a long, long time to come. People may get tired 
and not want to listen to it, but we'll have reasons to do it. And those reasons come 
back to one simple thing. It's our fathers and our mothers, our grandparents, our 
siblings, our kids, our nieces, nephews, our colleagues. All of these people who are 
unvaccinated, are at risk of becoming infected with this virus. And I've said many times, 
and I will continue to say it, this highly infectious virus, transmitted by the respiratory 
route, doesn't care if you think that you can basically wait out the clock and be at the 
end of the pandemic okay, but not having been vaccinated. This flu virus will find you. It 
will find you and you will wish you had been vaccinated at some point. So today, our job 
continues to be reminding people this is not going away, that despite the fact it is a 
semi-euphoria in many parts of the United States, that the pandemic's over, it is not 
over globally. And until it's over globally, it won't be over here either in terms of what the 
variance may bring us, even with this amazing miracle vaccine that we have. So I hope 
that that sets the table for what we're about to discuss for the rest of the podcast. That's 
where I'm coming from and coming with great humility. 
 
Chris Dall: [00:13:15] As we've been discussing over the past few episodes, the more 
transmissible Delta variant is driving the surge in many countries. What else are we 
learning about the transmission of this virus around the world? 
 
Michael Osterholm: [00:13:27] One of the things we're learning about this virus is that 
we can't count on it being like a flu virus. I see many, many people who have tried to 
take the influenza pandemic model and suggest that, well, you know, within two to three 
years at most, this is going to morph into the seasonal model. Meaning seasonal flu 
occurs after two or three years and various surges that occur with the influenza virus. At 
this point, I don't think we have any sense of what's going to happen long term. What 
does this mean in terms of of one day will this just become a seasonal virus? Let me 
just give you a sense of what I'm talking about. One of the things that we have to 
understand is that if you know Delta epidemiology in any one given week, you know 
Delta epidemiology for that week. If you think about what's been happening over the 
course of the duration, one of the things has been the repeated surgeries in countries. 
Month after month after month, these are occurring. For example, just just take a look at 
Iran. They are now in their fifth surge, fifth surge. And we talked at one point about after 
one or two surges, having enough people infected and protected with immunity that 
these surges wouldn't continue, much like we'd see with influenza. You know, you can 
have a three, maybe four surges at most, and then it moves on into the classic seasonal 
flu model. In Iran, their first surge was in late March, early April 2020, major impact. 
Second surge was in early June 2020. The third surge was in November to mid 
December 2020. And they had a fourth surge in late March, mid-May. I heard numerous 
people say at that point, well, now they had finally likely hit that threshold of what some 
call herd immunity. They had enough people infected and now they're in their fifth surge 
and it may be the worst one of all. So I think if you if you look at this and realize that 
there are a number of countries, I can just go through a very brief list of Peru, Brazil, 
Argentina, Colombia, Chile, Portugal, Netherlands, Bahrain, Israel, Oman, Kuwait, 
Kazakhstan, Bangladesh. I mean, there's a whole number of these countries that have 
had multiple waves of infection over and over again. So I think at this point we could go 
for months in a given country and it could be relatively quiet, including the United States 
and then have it resurge again. When we talk about the US based cases, I will reflect on 
that because I think a lot of people assume that the quote unquote, quiet period that 
we've more recently experienced since January with the major decrease in cases since 
then, has all been due to vaccine. Vaccines, played a very key role, no doubt about it. 
But there are a lot of people who have not been vaccinated in this country who have 
also not been infected over the last four months, five months. Why? And we're going to 
talk about that a bit more. But to help you better understand what's going on globally, let 
me just kind of give you a snapshot as of this week. In mid-April of this past year, we 
saw case numbers globally hit an all time high, 5.7 million cases reported per week. 
Now, we know that's underreporting problems. There's all kinds of issues here that 
come to bear on what the actual number really means. But for the sake of a relative tip 
of the iceberg, where 5.7 million cases of those 1.4 million came from the Americas, 1.4 
million came from Europe, and over 2.27 million came from Southeast Asia, primarily 
India. Now, following that high peak, cases have dropped precipitously, particularly 
because of the issue of India case numbers dropping. So that if you look, for example, 
just over 2.5 million cases reported the week of June 14th, which at this point that kind 
of hit the low. And since that time, case numbers are coming back up again. June 21st, 
2.6 million, June 28th, 2.7 million. And now these have been due to upticks largely in 
case numbers in Africa, Europe and Southeast Asia, outside of India. We are at this 
point looking from a death standpoint, after nine straight weeks of decline in global 
deaths after nearly 97,000 were reported that week of April twenty sixth, we've now 
gone in June twenty first to 58,000 deaths, June 28th 54,000 deaths. But now, with 
Africa's death numbers going up, that number has leveled off. And I think we're going to 
see another ride up again. And so when we look at what's happening, we now have to 
understand that this is kind of like a classic whack a mole approach to understanding 
the transmission in these countries. For example, if you look at the United States right 
now has had a 14 percent decline in new cases in the past week, South America, 19 
percent decline, Central and South Asia, two percent decline. On the other hand, 
Europe, particularly certain Eastern countries and Russia have had a 36 percent 
increase. The Middle East and North Africa, nine percent increase, sub-Saharan Africa, 
14 percent increase. And now East Asia and Oceania, 23 percent increase. So it's kind 
of this cycle where it goes from one place to another to another to another. And I think 
at this point, that's one of the hallmarks we're going to see, are these countries with 
surges from different time periods. If right now we look at the 12 countries with the 
highest case rates four countries are in Asia and the Middle East, Mongolia, Cyprus, 
Kuwait and Oman. Four countries are in Africa, Namibia, Tunisia, South Africa and 
Botswana. Three of the countries are in Latin America, Colombia, Argentina and Cuba. 
And one of the countries in Europe, the United Kingdom. That's the top 12 countries in 
the world. Look how they're spaced all over. And so this is going to be a pattern that I 
think we're going to continue to keep seeing. We're going to watch some countries 
decreasing in numbers of cases and then other countries coming back up again. We're 
now seeing countries where there's increasing peak activity, Cuba, Guatemala, 
Honduras and the British Virgin Islands. Cuba specifically is facing a sharp spike in 
activity. And so this is going to continue to play out over and over again. Just quickly, if 
we look at Asia and the Middle East right now, we're seeing the seven day average for 
cases has been back on the rise since late June. Why is that? Well, as much as India 
has declined, we're seeing eight countries that are now at record highs Bangladesh, 
Cambodia, Indonesia, Myanmar, Thailand, Vietnam, Iraq and Kuwait. Indonesia with 
just 5.2 percent of their population fully vaccinated, Indonesia is now experiencing a 
steep rise in cases and deaths. They've reached all time record highs. Bangladesh, as I 
just mentioned, the same thing. Let me just move to some other areas of the world, 
Africa right now, Africa is in what they call a full scale third wave, with cases for the 
region reaching new pandemic highs and deaths quickly growing. Just a year ago, we 
kept asking ourselves why were cases not occurring in Africa and there were all kinds of 
explanations that people came up with today, none of them make any sense because, 
in fact, Africa is just like the rest of the world. The growth rate in cases for the entire 
African region is higher than it's ever been. Both north and south of the equator, again 
suggesting that seasonality is not the key issue there. South Africa, which is 
experiencing a record high third wave of cases with deaths also quickly increasing. The 
country's president just described this past week the latest wave as devastating and 
stated that it was causing South Africa's health care system to completely buckle. Look 
at Europe at this point. With more than 1.6 million cases reported throughout Europe the 
week of March 22nd, the big peak, the region experienced 12 consecutive weeks of 
decline, falling to less than 340,000 cases the week of June 14th. But now look what's 
happening. In the past two weeks, they've gone from 340,000 cases to three hundred 
eighty eight thousand cases last week. This week they're at 532,000. They're coming 
back. A summer type surge. Although no countries or regions are reporting peak 
activity, current trajectories in places such as the U.K., Portugal, Russia, Spain, Greece 
and Luxembourg have generated real major concern. So if we try to understand the 
international picture, clearly vaccine plays a role in some of the countries. But for most 
of the countries where a vaccine really is not a major factor, then we have to realize this 
is the natural history of this virus. It will come and go. Why does it come and go? What 
is it that means it may impact an area for three, five, eight, 10 weeks? We don't know. 
Then be quiet and then come back again weeks to months later. That's the pandemic of 
the future we're going to see with this global scenario. 
 
Chris Dall: [00:22:58] Turning to the United States, the Delta variant now accounts for 
roughly 50 percent of new cases nationwide, and it's driving new cases and 
hospitalizations in several states, most notably Missouri and Arkansas. So, Mike, is this 
going to be similar to the trajectory of the alpha variant, which only caused significant 
surges in a handful of states? Or could this be different? 
 
Michael Osterholm: [00:23:20] Well, anyone who is going to project what these 
variants are going to look like three months, six months from now are looking into a 
crystal ball that is covered with six inches of mud because I don't think anyone can, with 
any real expertise, say what's going to happen. Let me just share kind of a general 
update what we're talking about with the variance. We've already discussed the Delta 
variant. I'll just say right up front right now. Fifty one percent of the current viruses being 
identified in the United States over the course of the past week to 10 days are, in fact, 
the Delta variant. But let me give you a sense of what the WHO leadership has been 
saying about these variants and where they're at. Over the past couple of weeks, 
there's been heavy emphasis on how the world's path forward with this virus is really 
challenged by this real wild card called a variant. Tedros, the director general of the 
WHO said this past week, "we are in a very dangerous period of this pandemic. In those 
countries with low vaccination coverage, terrible scenes of hospitals overflowing are 
again, becoming the norm. But no country on earth is out of the woods yet. There is 
now some sharing of vaccines happening, but it's still only a trickle which is being 
outpaced by variants." That's a pretty stark description of where we're at, but I think it's 
an accurate description. Maria Van Kerkhove, who is one of the leaders in the covid 
activity at WHO said this past week, "we don't have a crystal ball to see how long this 
will last. The virus is evolving and there will be more variance. The trajectory in each 
country is up to the plans that are in place and the ability to implement them. And, of 
course, taking into account that the virus will do what it's going to do." In terms of Delta 
itself, Tedros said this past week, the Delta variant is dangerous and is continuing to 
evolve and mutate. It has now been detected, as we know, in 98 countries and is 
spreading quickly in countries with low and high vaccination coverage. It is reminiscent 
of what happened with Alpha, but it's also taking over in many of the countries where 
Alpha had dominated for so long. Now, one of the challenges, as you know, it has been 
with Delta is not that it's just more infectious. Remember, we've already talked about the 
fact that the alpha variant B117, was anywhere from 40 to 70 percent, some say as high 
as 100 percent more infectious than previous viruses. Now we're seeing that the Delta 
variant is at least 40 to 60 percent more infectious than Alpha. That's a pretty 
substantial increase. When we look at the issue of what happened with Alpha, we're 
seeing now Delta falling right behind, taking over and actually beginning to become that 
dominant variant that we're seeing there. The challenge is, of course, it's more 
infectious. We've already talked about that. There is real question as to whether it's 
causing more severe disease. Some of that I think is yet an artifact of which populations 
are getting infected, meaning older populations, younger populations, that by itself could 
have a big impact on what the apparent serious disease picture looks like. So there's 
more information that needs to be gotten for that. But the third issue, which has really 
caused us a lot of concern, it has been the issue about evading immune protection, 
whether it be from the vaccines or whether it be from the natural infection and immunity 
you develop from that. The public health England has really served as the international 
model for providing us data on what's happening in England, in particular with the 
variant and what it means. When they put out in June 25th a report looking at the 
capability of some level immune protection, particularly as relates to one dose of 
vaccines versus the second dose, when they looked at the vaccine effectiveness 
against symptomatic disease, and remember, they had the AstraZeneca two dose as 
well as the two dose Pfizer vaccine. When they looked at vaccine effectiveness against 
the alpha variant, at one dose, it was 49 percent against symptomatic disease. It was 89 
percent with two doses against symptomatic disease. When you looked at Delta, it was 
one dose with 35 percent compared to 49 percent with Alpha, and it was only 79 
percent with two doses compared to the 89 percent for Alpha. So it was clearly a 
reduction. If they looked at vaccine effectiveness against hospitalization, the same 
issue. For Alpha one dose of 78 percent, for Delta one dose was 80 percent. Both 
showing, I would call that remarkably good protection against hospitalization, but with 
two doses they both demonstrated high protection. 93 percent for two doses against the 
alpha variant. 96 percent against the Delta variant with two doses. So I think one of the 
messages we're getting here is, in fact, that these variants may actually cause 
breakthrough infections of actual disease, but it's a much less severe disease. It's much 
less likely to cause hospitalization and much less likely to cause death. Now, we have to 
understand that this is still an emerging issue. There's been a recent paper that's come 
out of Israel in the past several days suggesting that the level of protection, even 
against hospitalization and serious disease is much less associated with the Delta 
variant. I'm going to talk a little bit more about that as we talk about the United States 
picture right now. I think it's fair to say that the protection we're getting with two dose 
mRNA vaccines and the two dose AstraZeneca is really a remarkable level of protection 
against hospitalization and serious illness. Now, I'll come back to more in a moment and 
talk about the J & J single dose vaccine. At this point, I just also want to add that the 
other variants that are out there, there's a thing called Delta Plus, AY.1. This is the sub-
lineage of delta that contains additional mutations. If we look at Epsilon, which is the 
variant that originally was the B14271479 or the California variant. If we look at lambda, 
a new variant that's been identified in South America, all of these are really functioning 
in a very similar way. And we don't know if any of these are going to become important 
in terms of the occurrence of cases or whether the Delta variant will continue to be the 
dominant one or what the next one will be. At this point, the take home messages 
vaccine vaccine vaccine is still working against severe disease and hospitalizations. 
And we have to do whatever we can to get people vaccinated. And that's going to be 
our best weapon against the Delta virus. Let me just spend a couple of moments talking 
about what is happening in the United States right now with regard to the incidence of 
disease and where we see things going. Let me repeat a point I made earlier, that for 
those who have said, don't worry, the summer is not going to be a problem, it's going to 
be a surge in the fall and winter, I'd be very, very, very cautious about assuming that 
that's the case. What activity we're beginning to see right now suggests that, in fact, 
unlike B117 or alpha, which did not spread throughout the United States and cause 
serious disease in multiple states, every indication is right now the delta is beginning to 
do that. Well, why is that? Well, if you look at where we're at with vaccinations right now, 
if you take all comers, everyone, all ages, only 55 percent of the population have at 
least one dose. 47 percent fully vaccinated. Now, we realize that includes kids under 
age 12, which are not eligible for a vaccine yet, but nonetheless, they are part of the 
pool. They can become infected, they can become seriously ill and they can transmit 
the virus. If we look at those 18 and up, 67 percent in this country, we've had at least 
one dose. 58 percent are fully vaccinated. That fully vaccinated is not a reassuring 
number. Remember also, I pointed out earlier that even with one dose, the challenge 
we have with these variants in terms of while they may reduce serious illness and 
hospitalizations, they still may cause infection. If we look at the group 65 years of age 
and up the group clearly at highest risk for serious outcomes, 88 percent have one or 
more doses, which is great news. And 79 percent are fully vaccinated. Almost a fourth 
of all, the person 65 years of age and older are not yet fully vaccinated. And so we still 
have work to do there in terms of the potential incidence of serious illness. Now, if we 
look at our cases, what's happening, just as I pointed out before, we have these peaks 
and troughs of cases and things can turn on a dime in terms of what appears to be a 
decreasing problem. If we look at cases as of July 7th, right now, we have a seven day 
average of about 12,914 cases. Today, however, we were reporting over 23,000 cases. 
Over the last 14 days, there has been a 14 percent increase in cases. If we look at the 
actual number of tests being done that has dropped over 12 percent over the last 14 
days, and I suspect you're going to see that changing relatively soon, given the 
increasing number of cases. If we look at hospitalizations, which are a classic lagging 
indicator, meaning they only go up seven to 14 days after cases go up, right now we 
have 16,991 hospitalizations on average over the last seven days per day. That's a two 
percent decrease over the last 14 days. If we look at deaths, the same thing is 
happening. Seven day averages, about 250 deaths. That's a 19 percent decrease over 
the last 14 days. That would be expected to be reflective of what was happening two to 
three weeks ago. But if you look at what's happening over the last 14 days, I think this is 
where you see a very sobering picture. 31 states, including the District of Columbia, 
have reported increases in cases of which 21 states, including the District of Columbia, 
have reported increases of greater than 20 percent in the number of cases. This is 
clearly a very different picture than we've seen since late January. 21 states have 
reported increases in hospitalizations. Eight reported increases greater than 20 percent, 
very different than we have seen since the January peak. And the case numbers 
dropping. Let's just look at six different states that are showing the real impact of the 
Delta variant. In Missouri, case numbers are rising substantially, they've increased by 
43 percent in the last 14 days, hospitalizations have increased 25 percent in the last 14 
days. If you've been following the news media, you know that in southwestern Missouri 
and northwestern Arkansas, there's been a substantial increase in cases there, which 
intensive care units are filled. They're experiencing the worst days of the pandemic to 
date. In Arkansas, which is the neighbor I just mentioned there. They, too, have seen an 
88 percent increase in cases in the last 14 days. Hospitalizations have jumped 45 
percent during that same time period. In Arkansas, only 35 percent of residents are fully 
vaccinated. We're seeing substantial increases in places like Nevada, where now they 
have seen cases increased 42 percent in the last 14 days. Hospitalizations have gone 
up 62 percent during that same time period. Only 42 percent of the residents are fully 
vaccinated. Utah, cases have gone up 31 percent in the last 14 days. Hospitalizations 
34 percent in the last 14 days, 37 percent of residents fully vaccinated. Louisiana, 85 
percent increase in the last 14 days, hospitalizations up eight percent during that same 
time period. Only 35 percent of the residents fully vaccinated. Just two more to cover 
here. If you look at Wyoming, there they've had an 11 percent increase in the last 14 
days and cases, hospitalizations have gone up 12 percent during that same time period. 
Only 35 percent of residents fully vaccinated. And let me just conclude of Florida, where 
we actually have artificially low case numbers due to the way that they've now 
embarked upon their reporting. We do know, however, while case numbers may not be 
accurate in that state, hospitalizations have gone up 17 percent in the last 14 days. Only 
46 percent of residents are fully vaccinated. And at this point, Delta has become the 
dominant variant in the United States. Missouri is greater than 90 percent Delta. 
Arkansas, 80 percent. Nevada, 80 percent. Utah, 70 percent. Louisiana, 60 percent. 
Wyoming, 60 percent. And Florida is now at 46 percent. So you can see that these case 
increases are following where the Delta variant is actually emerging. Now, to put this 
into a little bit of additional perspective, what we're seeing really is an urban suburban 
community split. And what I mean by that is if you look at the rate of new daily cases, 
they've fallen below three per 100,000 residents in large cities like Atlanta, Boston, 
Chicago, Detroit, Houston, Minneapolis, New York, Philadelphia, San Francisco and 
Washington, D.C.. As a point of comparison, the national rate of new daily cases 
peaked last winter in those same areas over 75 per 100,000. They're now basically 
below three per 100,000. You say if you're in those locations, the pandemics over. 
However, but in less populated areas, but nonetheless very diverse throughout the 
country, areas that tend to be more politically conservative and skeptical of vaccines, 
the virus is now surging largely from the Delta variant. The states with the worst 
outbreaks that I just mentioned, Arkansas and Missouri, each with more than 60 new 
daily cases per 100,000, followed by Florida 10, Nevada 10, Wyoming nine and Utah 
eight per 100,000 cases. So that what we're seeing here is really this relationship to the 
under-vaccination now becoming the greatest single predictor of looking at what's 
happening with cases. To add one last piece to this, I just want to add what I think is 
really a remarkable number that should hopefully give all of us a reason to believe that 
the vaccines are our answer. If you look at what we're seeing in terms of number of 
deaths in this country, if you look for the month of May, the latest data we have from the 
CDC and well before the Delta variant took off, only about 150 of the more than 18,000 
covid deaths in May were in fully vaccinated people, or less than one percent. That 
translates to about five deaths per day attributed to fully vaccinated Americans, 
experienced from breakthrough infections, particularly in the older population. But that 
compares to 300 deaths per day in the unvaccinated population. So let me just repeat 
this. If you look at this, it translates to about five deaths per day in the fully vaccinated 
Americans, compared to 300 deaths per day in the unvaccinated. One final note, just to 
give you some sense of this. And clearly, this is not a population based number. This is 
a county based number. And some of these are smaller counties. But think about this. 
We have over a thousand counties in the United States right now where less than 20 
percent of the population has received even a single dose. That's remarkable. What is 
happening, why is this? And I just want to remind everyone that this virus will not 
discriminate. It will find all of you if you are not vaccinated, this virus will find you and it 
will have you. And you can't run out the clock on this. So I urge people to do that and do 
it. Now, please do not be swayed into some kind of complacency because people keep 
talking about the fall/winter surge. We're seeing that surge beginning to emerge right 
now in this country, in those areas with under vaccinated populations. 
 
Chris Dall: [00:40:11] So, Mike, you've laid out the danger is that the Delta variant in 
particular poses to the unvaccinated, but I think that there are many listeners out there 
who, while fully vaccinated, are still concerned about the Delta variant and how much 
protection they have against it and are wondering about whether booster shots may be 
needed, especially those people who received the Johnson and Johnson single dose 
vaccine. What can you tell our listeners at this point about potential need for boosters? 
 
Michael Osterholm: [00:40:40] I've surely covered for you how both the mRNA 
vaccines and at least the AstraZeneca as a adeno-vaccine platform work and how 
important they are to get those we are all struggling with. What does a one dose J&J 
vaccine mean, when we talk about one dose data or two dose data? And this has been 
a real struggle for me personally. I'll just tell you up front, I have surveyed 21 of my 
colleagues who I have great respect for. These are the people that I would go to if I 
were trying to get the kind of advice that I'd want for one of my family members who are 
ill. And of those individuals, all of them but one said, you know, I would definitely 
recommend to individuals to get a booster dose of an mRNA vaccine if I had one dose 
of J&J. One individual said I would only recommend to high risk individuals for severe 
disease, people who are immune deficient, immune compromised, that they would do 
that. And I have felt really uncomfortable in the regards of having kind of what might be 
considered by some as this inside professional information. And while it has been 
discussed in the media, you haven't seen many people coming out just saying do it. And 
and I think that's not fair, we should have this is a public discussion, but it calls the 
question as to why don't we have more data on J&J? Well, I already mentioned before 
only about 12 million doses of one dose J&J vaccine have been administered in this 
country, which is just a small percentage of all vaccine doses. So we haven't had that 
much experience yet with it. The Brits did not, in fact, use J&J so they could not factor 
that into their analyses. But I think the real challenge we have right now is why don't we 
have more information even here in the United States that could at least provide 
direction to the public? None of us, at least I surely don't want to be the one saying I'm 
smarter than the ACIP or the FDA and therefore follow my advice on what to do with a 
vaccine versus theirs. We all know that would be irresponsible in a way. And yet when 
we talk about our own families and what we would do in that kind of off label concept, 
why shouldn't the public know about that? Now, there was a study that came out this 
past week that suggested, based on eight patients and following up on their immune 
response as J&J recipients in terms of in the laboratory, would their immune response 
to their antibody levels or t cell activity, would it protect against a serious illness, 
hospitalization or likely even fully protecting you against clinical infection? In the data 
suggested the one dose J&J would do that. That's a real paucity of data. We need more 
information. So I I've urged my colleagues at the federal level at the highest levels of the 
federal government. We need more clarity on this right away. And I very much support 
the fact my one colleague who said, you know, I would recommend this to anyone who's 
immune compromised to immune deficiency, that may not respond well to one dose. As 
we've seen, even with the mRNA vaccines, in some cases, three dose approach may 
be the right approach for those who have this underlying condition. I would say to you, if 
you are one of those individuals and you have received one dose J&J, get an additional 
dose of mRNA vaccine. I know I'm not a clinician. I'm an epidemiologist. I surely am not 
the FDA or the ACIP, but I'm trying to reflect what has been my experience with the 
people I most respect and admire in this business. And that's what they're telling their 
private family members, colleagues, friends, etc.. So I hope that in the end, we find that 
that's not the case. I do have concerns about the J&J vaccine data. We know from it's 
the work that was done with the beta variant and how that actually was a situation 
where the vaccine only provided, at best, moderate protection against clinical disease, 
that it would somehow, after one dose, provide high level protection against Delta or 
even for that matter, you know, really good protection against serious illness or 
hospitalization. So this is one we have to resolve quickly. It's one that we don't have the 
answer to at this point other than to say rather be safe than sorry. Now, some people 
are going to have a hard time getting a second dose of any vaccine if they've had J&J. 
I've had many friends who have said they've been turned down because their insurance 
company keeps track of who's gotten vaccinated and they go to a pharmacy or to a 
doctor's office and they're denied access to a second vaccine. This is really, I think, 
unacceptable at this point. We need to get this figured out as quickly as possible. So I 
implore my colleagues at the federal level, please bring as much information to the table 
and clarity as you can, even with incomplete information. 
 
Chris Dall: [00:45:59] So, Mike, this brings me to something I mentioned in the 
introduction, how public health experts, doctors and government officials communicate 
about where we go from here. So on the one hand, we're getting the message that the 
worst of the pandemic is in the past. But many people still have questions about 
vaccine's efficacy in the face of the variance about the need for booster shots and about 
whether we should still be wearing masks in certain situations. And answers seem to be 
all over the place. So do we need a new focus on what the message should be about 
living with this virus? 
 
Michael Osterholm: [00:46:34] Well, as I have said on repeated occasions on this 
podcast, we have had to go through the painful, painful months and months of learning 
how to die with this virus and what that means to us. And we are now in a period where 
it is important to emphasize how do we live with this virus? What does that mean? The 
masking issue is a good example. What does it mean in terms of trying to get people 
vaccinated? Can we feel safe going back into public spaces where a substantial number 
of people will not be vaccinated and not wearing any kind of respiratory protection? And 
I think at this point, the challenge we have is coming through with clear and compelling 
information about what we know and don't know. I think we need to take a page from 
our colleagues at Public Health England who have put out a series of publications 
based on the data that they have generated with cases, the epidemiology of the 
vaccine, effectiveness, all the issues that they've done there. And they've put them out 
in such a timely manner. And they've combined that with their professional advice as to 
what it means or doesn't mean in terms of the data. We've not done a good job with 
that. I, I have nothing but the highest compliments for the vast majority of work that this 
administration has done to get vaccines out. I've said multiple times, this is totally an 
apolitical comment, but we are very fortunate to have a vaccinator in chief. President 
Biden has done everything that you could ever hope for of someone being a public 
spokesperson and and continuing to keep that message front and center. I have nothing 
but the highest respect for him, but that's not a political statement that's just based on 
the reality of what he's done. But where I really have concerns right now is this lack of 
clarity, like the J&J vaccine, like the issue of masking, because every time one of these 
debates ends up in the public media, we just lose credibility, we lose credibility as public 
health, and we need to be anticipating these, we need to be thinking about what are the 
next 10 questions that are likely to emerge in the next one month that we could get on 
now that we could actually begin to address. So we have something to tell people and 
we have some way of building a consensus among our public health colleagues. What 
does this mean? You know, does it help to have, you know, one of the major counties in 
this country say everybody needs to wear a mask and then the CDC director say, no, 
you don't. And then the leading NIH experts saying, well, he wears one in a public 
setting. So we have to avoid that. And it's understandable why it occurs because there 
is incomplete information. It's not like somehow I have all the answers either. But we 
should be anticipating these questions. We should be. You know, the idea of what this 
summer might look like. Well, right now, here's an example. We are beginning to see a 
whole series of major outbreaks occur with summer camps. It's remarkable. Just in the 
last 10 days. Are we on top of that? What does that message mean for so many of our 
kids that are going to summer camps? You know, I don't want to wait until we have the 
13th outbreak, of which several people die. That makes the front page of all the major 
media venues in the United States and then we have to address it. So I have had these 
discussions at a very private level with, again, my colleagues at the highest level of 
government. We need to do a better job. And we're not. I can't tell you how many 
people today call me, email me and say I have this kind of underlying immune 
deficiency, what should I do? I go to my doctor and they don't know what to do either. 
You know, for us to send people to their general practitioner to get this kind of advice is 
absolutely wrong if we're not giving them that advice themselves, meaning if we're not 
providing the background, all we've done is defer to difficult question to somebody who 
is less prepared to answer than the people who deal with it every day. And that's wrong. 
So I think we are leaving a lot of our frontline clinicians really at the mercy of what 
they're getting out of their local newspapers or national newspapers. And so we need to 
have a whole new focus on communication and how we deal with it. And so I'm hopeful 
that we can do a better job. Health England has surely, I think, given us a way to look at 
that. So let me just conclude by saying we must do a much better job. We owe it to the 
public. We owe it to our medical community. We owe it to public health leaders. What 
are those substantive key issues that we must provide advice on even if we don't have 
all the information? And how are we going to get that information if we haven't to date? 
So I'm sorry we haven't done a better job. I don't think we have. And I think that today 
that should be one of the highest priorities of this country is to help clarify how do we 
message about this pandemic and what does that mean? 
 
Chris Dall: [00:51:53] So now to our covid query segment, this is where we try to 
answer questions about the decisions that you are listeners are trying to make, the 
situations you're trying to navigate and the risks you're assessing on a daily basis in this 
post vaccination covid world. Our covid query this week is from conference skeptic who 
wrote, Hi, Dr. Osterholm and CIDRAP team. I'd love to get your perspective on 
attending a large medical industry conference in Boston at the end of July. In the before 
times, his annual conference was attended by more than 10,000 physicians and 
industry professionals from around the world. This year's conference will be a 
combination of online and in-person. Although in-person attendance will be much lower 
this year, maybe closer to three to five thousand. They already have people registered 
from dozens of countries. There's no vaccination requirement for attendees and no 
mask mandate on sight, either by the Commonwealth of Massachusetts or by 
conference organizers. Meeting attendees will be in convention center rooms listening 
to presentations and visiting industry booths in the exhibit hall. Do you think attending is 
relatively safe for someone who's fully vaccinated with no particular risk factors? Or do 
the Delta variant, the potential for other as yet unknown variants, and lack of data 
around vaccine effectiveness with the newest variants warrant sitting this one out? 
Another point of consideration. I'm going to be up north on a family vacation in the 
following week with my 81 year old mother, who was fully vaccinated in March. So, 
Mike, what would you tell a conference skeptic? 
 
Michael Osterholm: [00:53:18] This is one of those issues that it's not about the data. 
You know, we all want to have some number that we can internalize and then make a, 
quote, unquote, scientific decision. This is about how comfortable do you feel? You 
know, 38,000 individuals dying each year on our highways in the United States. How 
many of us do not get into a car for that reason? It's what we're comfortable with is what 
we believe that that's just part of our everyday life. I have to say, as someone who is 
over age 65, who has been vaccinated with mRNA vaccines, both doses, you know, I 
don't know if I'd feel comfortable being in a setting like that where the likelihood of 
someone being infected in that room without knowledge of who's been vaccinated and 
who's not is real, particularly with individuals coming from around the world. And so I 
understand where some would say, what do you mean, come on, that risk is very low. 
What's the chances of that happening? You know, I'll say, well, what's the level of 
vaccination in that group? You'd hope because of the type of meeting it is, most people 
would be vaccinated. Are they coming from a part of the world they can get access to 
vaccine? Likely if they're in the medical community as such. But I think that this is what 
we really haven't addressed yet is how do we process and work through this type of risk 
analysis. So personally, I wouldn't go to a meeting like that just because I'm not 
comfortable yet in that setting. And I can't explain exactly why or why not, any more 
than I can explain to you why I am absolutely comfortable getting in my car every day 
and driving somewhere, particularly in bad traffic in inner city areas. So I think to me, I'm 
unfortunately not going to give you a comfortable answer. But if you're someone with 
both doses of vaccine, no underlying health conditions, I've already shared with you the 
percentage of those who are dying, who are actually fully vaccinated, very, very, very 
low, then you may come to that conclusion. This is fine. I feel comfortable in there or 
you may come to the conclusion I'm not ready yet. And both of those are the right 
answer. Both of those are. And I think that's the important thing. Feel right about 
yourself and then you'll do the right thing. And so thank you for your question. Also, with 
regard to the family vacation the following week, that includes your 81 year old mother. 
Two things I guess I would add here is that, one, it sounds as if there's other people 
going to be on the vacation with you. And the most important thing for your mother is to 
surround her with vaccinated, protected people. So I hope that the family makes that a 
priority. The second thing is, while your risk is extremely, extremely low of going to the 
conference in Boston and getting infected there, as someone who has had both doses 
of vaccine with no underlying immune deficiencies, but the point being is, is that you 
would be yourself infectious, likely a week later if you should have a breakthrough 
infection, which then then means that you would potentially be in a place to infect your 
mother. We're still working on getting more data on how often breakthrough infections 
mean that people are actually infectious themselves. It likely is less than that of if you've 
never been vaccinated. But that still is an open question. So to me, I would say at this 
point that should factor into your Boston trip, too, if you want to, not to put your mother 
at any increased risk, even a very, very small you likely would say, I don't want to be 
potentially coming down with a covid-19 infection at the very time I'm on this vacation 
with my mother. But again, it's going to be about how do you surround her? How do you 
bubble her with vaccinated people? 
 
Chris Dall: [00:57:13] And to our listeners, please keep those questions coming, you 
can email us at osterholmupdate@umn.edu. So Mike, in our last episode, you asked 
our listeners to send us a few words or paragraphs about a beautiful or special place 
that has meaning to them. And we're going to close out this episode of the podcast with 
an email from a listener in Michigan. What's this week's Beautiful Place, Mike? 
 
Michael Osterholm: [00:57:37] First of all, I want to thank all of you who submitted 
finding beauty in our world and sharing that with us, that they were really very touching. 
And I think as an audience, you will all appreciate the the kind of visual image and the 
warm heart feeling that these can give. This one comes from Carol and Carol wrote, 
Fortunately, I have no stories of heartbreaking loss during this pandemic. My husband 
and I are mostly retired and hunkered down for the duration. Our daughter was in 
Canada, unreachable and the best gift we could give her was peace of mind that we 
were doing all we could to remain healthy and uninfected. Marquette, Michigan, is on 
Lake Superior. There is a gorgeous mile long bike path that hugs the shoreline. We 
made it our resolve to walk it twice a day. As much, we're getting out of the house to 
exercise for simply filling the long days. Each day, we eagerly took note of the new 
wildflowers appearing, the chokecherries ripening, the pollinators arriving. Most every 
day, we would spot an eagle soaring high above us. After a rain, we could see the 
glistening webs of orb weavers. The plant that became most important to us, though, 
was the common milkweed. Its fragrant blooms last a long time and each day we used it 
as our health barometer. Can you smell it? We would ask each other with a smile and 
hope we both answered yes. The beautiful milkweed. When the plants went to seed, we 
collected a few pods to try to have some for ourselves outside our own door. This 
summer is a bit different. We are fully vaccinated but have fallen in love with the 
shoreline walk. This week the milkweed started to bloom and we again asked, Can you 
smell it? But the fear is gone. That fragrance will forever remind us of our covid year 
and we are so grateful for the science that brought us this lifesaving vaccine, but also 
grateful for the opportunity to stop and smell the milkweed. Sincerely, Carol, from 
Marquette, Michigan. Carol, thank you for that very thoughtful image and wonderful 
message. It is something we all need right now. So it's a special gift to us, to all the 
listeners. And please, as Chris noted, please send us more of these. We will get them 
on the air the best we can. And let me just leave you all this week with kind of that final 
word of saying, I'm sorry, I couldn't give you more direction, more specific information 
on what this pandemic is going to do. I have such respect for this virus. It's a foe. It is a 
real foe and it is one that is ruthless. It is one that we still can have a upper hand 
advantage if we're vaccinated, but it's one that if we decide not to do that, doesn't care 
what our political, religious or other beliefs were, why we didn't get vaccinated. It's one 
that still may prey upon those who are immune compromised or immune deficient, not 
through any fault of their own. We need to do what we can to get you better and more 
specific information, how we can protect you. So I leave you today with the hope that 
over the course of the next weeks, we do convince more and more people to get 
vaccinated and that we as a world do everything we can to get vaccine to those low and 
middle income countries. We need about 10 Manhattan projects to make vaccine and 
we need a thousand Marshall plans to get it into everyone's arm around the world. If we 
could do that, then we could end these podcasts, we could put this into the history 
books and call it done and over. But until we do that, we can't. And I just come back and 
remind us all something that I think most of the people on this podcast do not need to 
remind you of, but it's still something that is at least useful in terms of bringing us back 
to reality. Is it all of these cases, all of these deaths that I talked about today are our 
mothers and our fathers, our brothers and our sisters, our children, our aunts and 
uncles, our colleagues, people we admired and people we care about. That's why we 
have to get people vaccinated. So thank you for spending your time with us. We 
appreciate it. And and keep the cards and letters coming in. We do read them all. I 
promise you we do. So thank you very much and look forward to talking to you in two 
weeks. Thank you. 
 
Chris Dall: [01:02:31] Thanks for listening to this week's episode of the Osterholm 
Update. If you're enjoying the podcast, please subscribe, rate, and review. And be sure 
to keep up with the latest covid-19 news by visiting our website CIDRAP.umn.edu. This 
podcast is supported in part by you, our listeners. If you would like to donate, please go 
to CIDRAP.umn.edu/donate-now. The Osterholm Update is produced by Maya Peters, 
Cory Anderson and Angela Ulrich. 
 
